NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer (NSCLC) will be reported in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois..

纽约--（商业新闻短讯）--Nuvation Bio Inc.（纽约证券交易所：NUVB）是一家晚期全球生物制药公司，通过开发差异化和新型的治疗候选药物来解决肿瘤学中一些最大的未满足需求，今天宣布，将在2024年5月31日至6月4日于伊利诺伊州芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会上口头报告来自第二阶段TRUST-I临床研究（NCT04395677）的最新数据，该研究评估了中国ROS1阳性非小细胞肺癌（NSCLC）患者的塔利替尼。。

Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the potential treatment of patients with ROS1-positive NSCLC.

Taletrectinib是一种口服，有效，中枢神经系统活性，选择性的下一代ROS1抑制剂，专门用于ROS1阳性NSCLC患者的潜在治疗。

Taletrectinib is being evaluated for the treatment of patients with ROS1-positive NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study.

Taletrectinib正在两项2期单臂关键研究中评估ROS1阳性NSCLC患者的治疗：中国的TRUST-I（NCT04395677）和全球研究TRUST-II（NCT04919811）。

Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced or metastatic ROS1-positive NSCLC. Based on results of the TRUST-I clinical study, China’s NMPA has accepted and granted Priority Review Designations to New Drug Applications for taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who either have or have not previously been treated with ROS1 tyrosine kinase inhibitors (TKIs)..

Taletrectinib已被美国食品和药物管理局（FDA）和中国国家医药产品管理局（NMPA）授予突破性治疗指定，用于治疗晚期或转移性ROS1阳性NSCLC患者。根据TRUST-I临床研究的结果，中国NMPA已接受并优先审查了用于治疗局部晚期或转移性ROS1阳性NSCLC的成年患者的他列替尼新药申请，这些患者以前曾或未接受过ROS1酪氨酸激酶抑制剂（TKIs）治疗。。

About Nuvation Bio

关于Nuvation Bio

Nuvation Bio is a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC).

Nuvation Bio是一家晚期的全球生物制药公司，通过开发差异化和新颖的治疗候选药物来解决肿瘤学中一些最大的未满足需求。Nuvation Bio的开发候选者组合包括taletrectinib（ROS1），safusidenib（mIDH1），NUV-868（BET）和NUV-1511（DDC）。

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/..

Nuvation Bio于2018年由生物制药行业资深医生David Hung医学博士创立，他之前创立了Medivation，Inc.，该公司为患者带来了世界领先的前列腺癌药物之一。Nuvation Bio在纽约、旧金山和上海设有办事处。有关更多信息，请访问www.nuvationbio.com和https://www.linkedin.com/company/nuvationbio/..